Project 450992
Therapeutic potential of the LXA4-ALX/FPR2 axis in osteoarthritis
Therapeutic potential of the LXA4-ALX/FPR2 axis in osteoarthritis
Project Information
| Study Type: | Unclear |
| Research Theme: | Biomedical |
Institution & Funding
| Principal Investigator(s): | Fahmi, Hassan |
| Co-Investigator(s): | Martel-Pelletier, Johanne; Pelletier, Jean-Pierre |
| Institution: | Centre hospitalier de l'Université de Montréal (CHUM) |
| CIHR Institute: | Musculoskeletal Health and Arthritis |
| Program: | |
| Peer Review Committee: | Clinical Investigation - B: Arthritis, Bone, Skin and Cartilage |
| Competition Year: | 2021 |
| Term: | 5 yrs 0 mth |
Abstract Summary
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of disability in Canada and worldwide. It has a large impact on the patient's quality of life, and constitutes a significant socioeconomic burden. There is currently no effective treatment for OA. Therefore, the need to develop an effective therapeutic strategy is an urgent necessity. The overarching goal of our studies is to improve our understanding of the molecular mechanisms underlying the pathogenesis of osteoarthritis with the ultimate goal of developing more effective treatments. Our recent studies strongly suggest that the enzyme, Lipoxin A4 and its receptor ALX/FPR2 have protective properties in OA. In this project, we will use animal models of OA and human sera and synovial fluids to define the role and the therapeutic potential of this pathway in OA. These studies will improve our understanding of the pathogenesis of OA and may be helpful in developing novel efficacious anti-OA therapeutic strategies.
No special research characteristics identified
This project does not include any of the advanced research characteristics tracked in our database.